Durham、NCにおける乳がんの臨床試験
Durhamとその周辺地域（約30マイル以内）の拠点で、乳がんに関する64件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Duke University, Durham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Duke Cancer Network, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Durham VA Medical Center, Durham
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
被験者募集中第2相健康なボランティア歓迎
- University of North Carolina, Chapel Hill · 10マイル先
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
被験者募集中第2相
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
Radiation Therapy and Thymus Function in Young Women With Breast Cancer
被験者募集中観察研究
- Duke Cancer Center, Durham
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
被験者募集中第1相
- Duke Cancer Center, Durham
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
被験者募集中観察研究健康なボランティア歓迎
- University of North Carolina, Chapel Hill · 10マイル先
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- Duke Cancer Institute, Durham
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Duke University Medical Center, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- University of North Carolina Medical Center, Chapel Hill · 10マイル先
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
被験者募集中第2相
- University of North Carolina Medical Center, Chapel Hill · 10マイル先
Identifying Patterns in the Breath of Individuals With Breast Cancer
被験者募集中観察研究健康なボランティア歓迎
- Duke University Medical Cente, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
被験者募集中第2相
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
被験者募集中第2相
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10マイル先
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Duke Cancer Institute, Durham
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
被験者募集中観察研究
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
被験者募集中第1/2相
- Duke Cancer Institute, Durham
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Duke Cancer Institute, Durham
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
被験者募集中第1/2相
- Duke Cancer Institute, Durham
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Duke Cancer Institute, Durham
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
被験者募集中第2相
- Duke University, Durham
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
- University of North Carolina-Hillsborough Campus, Hillsborough · 13マイル先
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
被験者募集中健康なボランティア歓迎
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Optimizing Surgical Decisions in Young Adults With Breast Cancer
被験者募集中
- Duke Cancer Institute, Durham
A Novel Approach Utilizing Organ Specific Age Proteomics
被験者募集中観察研究
- University of North Carolina, Chapel Hill · 10マイル先
Weight Management After Cancer for Survivors in Rural Communities
被験者募集中
- Duke University Medical Center, Durham
Behavioral Pain Intervention for Older Cancer Patients
被験者募集中
- Duke Cancer Network, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
被験者募集中第2/3相
- Duke Cancer Institute, Durham
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
被験者募集中
- Duke University/Duke Cancer Center, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
被験者募集中第2相
- Duke University Medical Center, Durham
Planning Grant for TOPS for Breast Cancer Survivors
被験者募集中
- Duke University, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
被験者募集中
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10マイル先
A Study of a Decision Tool for People Considering Breast Reconstruction Surgery
被験者募集中
- Duke Cancer Institute (Data collection only), Durham
- Duke Cancer Institute (Data collection only), Durham
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
被験者募集中観察研究
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10マイル先
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
被験者募集中第3相
- Duke University Medical Center, Durham
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
被験者募集中第1相
- University of North Carolina, Chapel Hill · 10マイル先
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
被験者募集中第2相健康なボランティア歓迎
- The University of North Carolina, Chapel Hill · 10マイル先
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
被験者募集中観察研究
- University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
被験者募集中
- University of North Carolina, Chapel Hill · 10マイル先
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
被験者募集中第2相
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10マイル先
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
被験者募集中第2相
- The University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
被験者募集中第2相
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
被験者募集中
- Duke University, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Duke Cancer Center/ DUMC, Durham
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
被験者募集中観察研究
- UNC, Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
被験者募集中第2相
- University of North Carolina, Chapel Hill · 10マイル先
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Duke Cancer Institute, Durham
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
被験者募集中
- UNC Cancer Hospital, Chapel Hill · 10マイル先
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
被験者募集中
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
被験者募集中
- Duke Cancer Institute, Durham
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
被験者募集中
- Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill · 10マイル先
BREAST Choice Decision Tool R21 - AIM2
被験者募集中健康なボランティア歓迎
- The University of North Carolina, Chapel Hill · 10マイル先
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
被験者募集中
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 10マイル先
UNC Pleural Fluid Registry
被験者募集中観察研究
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 10マイル先
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
- Arlington, VA47件の研究
Durhamにおける他の研究
- がん（全種類）58件の研究
- 非小細胞肺癌39件の研究
- 多発性骨髄腫37件の研究
- 急性骨髄性白血病33件の研究
- 転移性癌33件の研究
- 前立腺がん32件の研究
- 肺がん32件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 慢性リンパ性白血病27件の研究
- 心不全26件の研究
- 膵臓がん24件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。